Prior Authorization Criteria 2014
|
|
- Kristin Waters
- 8 years ago
- Views:
Transcription
1 Prior Authorization Criteria 2014 For information on obtaining an updated coverage determination or an exception to a coverage determination please contact Easy Choice Health Plan of New York s Member Services at or, for TTY/TDD users Our hours of operation are Monday through Friday from 8:00 AM to 8:00 PM from February 15, 2013 to September 30, 2013; 7 days a week from 8:00 AM to 8:00 PM from October 1, 2013 to February 14, 2014; Monday through Friday from 8:00 AM to 8:00 PM from February 15, 2014 to September 30, 2014 or visit No changes made since 05/01/2014 1
2 Table of contents Actemra... 5 Actimmune... 5 Adcirca, Sildenafil... 6 Aldurazyme... 6 Ampyra... 6 Analgesics (High Risk Medications)... 7 Androgens (High Risk Medications)... 7 Apokyn... 8 Aralast, Zemaira... 8 Aranesp... 9 Arcalyst... 9 Arixtra Attention Deficit Hyperactivity Disorder Agents (High Risk Medications) Aubagio Avonex Benlysta Benzodiazepines Betaseron Botox Butrans Cayston Cerezyme Cesamet Chorionic gonadotropin, Pregnyl Cialis Cimzia Cinryze Copaxone Dementia Agents (High Risk Medications) Effient Elaprase Eleyso Eligard, leuprolide Emsam Enbrel Epogen Fabrazyme Fentora Ferriprox Firazyr Flector Forteo
3 Gastrointestinal Agents (High Risk Medications) Gattex Gilenya Glassia Gleevec Humira Ilaris Incivek Increlex Infergen Intron-A Itraconazole Juxtapid Kalydeco Kineret Kuvan Kynamro Letairis Leukine Linzess Lumizyme, Myozyme Lyrica Mozobil Neulasta Neumega Neupogen Octreotide, Sandostatin, Zorbtive Oral Estrogens (High Risk Medications) Orencia Pegasys Peg-Intron Prolastin-C Promacta Qualaquin Relistor Remicade Revlimid Sabril Somatropin Somavert Sulfonylureas (High Risk Medications) Tarceva Testosterone Tetrahydrocannabinol Tracleer Trelstar
4 Tretinoin (topical) UTI Antibacterials (High Risk Medications) Vasodilators (High Risk Medications) Ventavis, Remodulin Victrelis Vimpat Vpriv Xenazine Xgeva Xolair Xyrem Zoledronic Acid Zyvox
5 Actemra Diagnosis. Labs: ANC and Platelet Count.The patient must have had an inadequate response to conventional treatment including methotrexate with or without one or more disease modifying anti- rheumatic drugs (DMARDs) +/- NSAIDs for at least 3 consecutive months within the last 12 months, unless contraindicated or intolerant. The patient has had an inadequate response to one the TNF antagonist therapy Remicade, Humira, or Enbrel. An inadequate response can be defined as therapy was ineffective, not tolerated, or other clinical circumstance Required_Medical_Information exists that precludes use. Licensed Practioner highly familiar with the use and monitoring of special biologic response modifiers Actimmune Hypersensitivity to interferon gamma, E. coli derived proteins, or any component of the formulation. Treatment of IPF (not FDA approved) Medical documentation of FDA approved diagnosis of chronic granulomatous disease or severe malignant Required_Medical_Information osteopetrosis. Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. ONLY APPLIES to NEW STARTS 5
6 Adcirca, Sildenafil Coverage not provided for patients currently receiving nitrate therapy Patient has a diagnosis of Pulmonary Arterial Hypertension (PAH) WHO Group I with NYHA functional class II or III OR Patient has a diagnosis of Pulmonary Arterial Hypertension (PAH) (WHO Group I) WHO/NYHA functional class IV and documentation that the patient refuses IV therapy, is not capable of managing the complex delivery system, or is intolerant to or has contraindications to IV prostanoid Required_Medical_Information therapy (i.e. epoprostenol, treprostinil). Prescription is written by a pulmonologist or cardiologist or documentation of consultation with pulmonologist or cardiologist Aldurazyme Required_Medical_Information Diagnosis Patients must be greater than 5 years old Ampyra Coverage is not provided for patients who have a history of seizures, moderate or severe renal impairment (CrCl less than 50 ml/min) or is currently using any other forms of 4-6
7 aminopyridine. Required_Medical_Information Patient has a documented diagnosis of one of the four types of multiple sclerosis (MS) AND, Patient is ambulatory (able to walk with or without an assistive device, at least 25 feet in 8 to 45 seconds). Patient must be 18 years of age or older 3 months Renewal review: patient has demonstrated documented improvement by maintaining a stable walking speed without worsening of ambulation AND, at least a 20% improvement in the T25FW from baseline. Analgesics (High Risk Medications) Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication, OR, 2.) Patient has already tried and failed any TWO nonhigh risk formulary drug alternatives (narcotic analgesics) Required_Medical_Information Applies to patients 65 years or older Androgens (High Risk Medications) 7
8 Required_Medical_Information Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication. Applies to patients 65 years or older Apokyn Patient that has not been previously treated with standard dopaminergic therapy Advanced Parkinson s Disease: 1. Confirmed diagnosis of advanced Parkinson's disease, AND 2. inability to control 'off' symptom s with any TWO of the following drugs: levodopa/carbidopa AND a dopamine agonist (bromocriptine, pramipexole, or ropinirole) or COMT inhibitor (tolcapone or entacapone) AND 3. Used in combination with a non-5-ht3 antagonist antiemetic for initial therapy, AND 4. Not used in combination with 5-HT3 antagonists Required_Medical_Information Aralast, Zemaira 8
9 Required_Medical_Information Patients with IgA deficiency who have known antibodies against IgA, anaphylaxis or hypersensitivity to IgA products or components or a history of severe systemic response to A1-PI products. Diagnosis Aranesp Uncontrolled hypertension, known hypersensitivity to the active substance or any excipients, iron stores are inadequate, pre-treatment Hgb greater than 12 g/dl. Required_Medical_Information Diagnosis and the following Labs: Hgb, Ferritin, and Tstats 3 months Arcalyst Rilonacept is not considered medically necessary when members have the following concomitant conditions: Active Tuberculosis, HIV, Hepatitis B, Hepatitis C, Neonatal- Onset Multisystem inflammatory disease, or currently utilizing tumor necrosis factor inhibitors or interleukinn-1 blockers. Diagnosis of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome Required_Medical_Information (FCAS) and Muckle-Wells syndrome (MWS) The patient must be 12 years and older 9
10 Arixtra Required_Medical_Information Diagnosis Attention Deficit Hyperactivity Disorder Agents (High Risk Medications) Required_Medical_Information ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication, OR, 2.) Patient has already tried and failed any ONE nonhigh risk formulary alternative (Strattera) Applies to patients 65 years or older Aubagio Severe hepatic impairment. Current treatment with leflunomide. Patients who are pregnant or women of childbearing potential not using reliable contraception. 10
11 Required_Medical_Information Diagnosis of relapsing forms of multiple sclerosis (relapsing-remitting MS or progressive-relapsing MS) OR patient has experienced a first clinical episode and has MRI features consistent with multiple sclerosis. 18 years of age or older Avonex Required_Medical_Information Hypersensitivity to human albumin (Avonex(R) lyophilized powder vials and Rebif(R) prefilled syringes), hypersensitivity to natural or recombinant interferon Diagnosis from neurologist of definite or probable relapsing remitting MS, secondary progressive MS with relapses, or progressive relapsing MS. Statement may include a first MS attack with documented MRI scan abnormalities characteristic of MS, OR evaluation documenting EITHER: history of at least two focal neurological deficits (e.g. loss of vision, double vision, localized numbness or weakness), in which the first resolved and the second followed after a period of at least 6 months, OR history of one focal neurological deficit which has resolved, and documentation of an MRI suggestive of MS. Prescribing physician must be a neurologist 1 year, only extend for 3 months at a time beyond this duration Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Benlysta Receiving other biologic therapy or intravenous cyclophosphamide 11
12 Required_Medical_Information Diagnosis of active, autoantibody-positive (acceptable assays include ANA, anti-ds-dna, anti-sm, etc.) systemic lupus erythematosus AND patient is currently receiving one or more of the following standard therapies: corticosteroids, antimalarials, NSAIDs, immunosuppressants. 18 years of age or older Benzodiazepines Coverage not provided for contraindications to therapy: acute closed-angle glaucoma (with the exception of oxazepam) and for lorazepam injection only: sleep apnea syndrome or severe respiratory insufficiency except in those patients receiving lorazepam for amnestic effects while being mechanically ventilated. Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication, OR, 2.) Patient has already tried and failed any ONE nonhigh risk formulary alternative, OR, 3.) Prescriber has been made aware that the requested drug is a high risk medication and wishes to proceed with the originally Required_Medical_Information prescribed medication. Applies to patients 65 years or older Betaseron Hypersensitivity to E. coli-derived products, natural or recombinant interferon beta, albumin human or any other component of the formulation Required_Medical_Information Approvable for treatment of with a diagnosis of MS. 12
13 Prescribing physician must be a nuerologist Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Botox ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. Infection at the proposed injection site. Cosmetic use (e.g., wrinkles). Diagnosis of one of the following: A) strabismus, OR B) blepharospasm associated with dystonia, OR C) Urinary incontinence and condition is associated with a neurologic condition and Patient tried and had an inadequate response to at least one antimuscarinic agent, unless contraindicated or intolerant to antimuscarinics (e.g., narrow angle glaucoma) and patient does not have a urinary tract infection and patient is routinely performing clean intermittent self-catheterization (CIC) or is willing/able to perform CIC, OR D) Chronic migraine and medication will be used as prophylaxis and experiences headaches on 15 or more days per month lasting four hours or longer and patient has tried and had an inadequate response with at least two first-line therapies from two different therapeutic classes (i.e. antiepileptics, beta-blockers, triptans, and tricyclic antidepressants) OR E) Cervical dystonia (including spasmodic torticollis) F) Overactive bladder and has symptoms (e.g., urge urinary incontinence, urgency, and frequency) and patient has tried and had an inadequate response to at least one antimuscarinic agent, unless contraindicated or intolerant to anti-muscarinics (e.g., narrow angle glaucoma) OR F) Axillary hyperhidrosis and patient s condition significantly interferes with patient's daily activities and condition is refractory after 30 days of Required_Medical_Information treatment with topical aluminum chloride OR G) Upper limb 13
14 spasticity. 12 years of age or older - strabismus or blepharospasm Urinary incontinence - prescribed by or in consultation with an urologist Butrans Significant respiratory depression or severe bronchial asthma. Known or suspected paralytic ileus. The medication will not be used for one of the following: management of acute pain or requires opioid analgesia for a short period of time (management of post-operative pain, including use after outpatient or day surgeries), management of mild pain, or management of intermittent pain (e.g., use on an as needed basis). Patient is in hospice care (age restriction does not apply) OR Patient has a diagnosis of moderate to severe chronic pain requiring continuous, around-the-clock opioid analgesic for an extended period of time AND patient tried and failed, is unable to tolerate, or has a contraindication to at least one therapy from each of the following two drug categories: NSAIDs and generic extended-release opioid product and/or opioid combination product, unless the Required_Medical_Information patient has documented swallowing difficulties. 18 years of age or older (does not apply to hospice patients) Cayston 14
15 Required_Medical_Information Diagnosis of cystic fibrosis AND patient has evidence of P. aeruginosa in the lungs 7 years of age or older Cerezyme Diagnosis of non-neuropathic Gaucher s disease with one of the following: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly, it has been designated an orphan product for use in the treatment of types I and III Required_Medical_Information Gaucher's disease. Patient must be at least 2 years of age Cesamet Diagnosis of chemotherapy-induced nausea and vomiting AND patient has tried and failed conventional antiemetic treatments (e.g., aprepitant/fosaprepitant, dexamethasone, t-hydroxytriptamine-3 serotonin receptor antagonists, butyrophenones, phenothiazines, metoclopramide) AND Required_Medical_Information patient has tried and failed dronabinol. 6 months 15
16 Chorionic gonadotropin, Pregnyl Pregnancy or suspected pregnancy. Use for infertility or sexual dysfunction. Required_Medical_Information Diagnosis required Must be at least 4 years of age Cialis Coverage is not provided for erectile dysfunction without signs and symptoms of BPH or concurrent use with nitrates. Patient has a diagnosis of benign prostatic hyperplasia (BPH) AND 1.) Tadalafil 2.5 mg or 5 mg is being requested AND 2.) Patient has experienced intolerance to or treatment failure with an alpha-blocker (e.g. doxazosin, prazosin, tamsulosin) and a 5-alpha reductase inhibitors Required_Medical_Information (e.g. dutasteride, finasteride) Cimzia Active serious infection (including tuberculosis) 16
17 Required_Medical_Information Diagnosis of moderate to severe rheumatoid arthritis and patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs for at least 3 consecutive months OR Diagnosis of moderate to severe Crohn's disease and patient has an inadequate response to, is intolerant to, or a contraindication exists to conventional therapy with one of the following: corticosteroids (i.e. Entocort EC, prednisone, methylprednisolone). 18 years of age or older Patient has been tested for TB and latent TB has been ruled out or is being treated. Cinryze History of life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. Diagnosis of hereditary angioedema AND Medicaton will be Required_Medical_Information used for routine prophylaxis against angioedema. Copaxone Diagnosis of relapsing-remitting multiple sclerosis OR diagnosis of first clinical episode with MRI features Required_Medical_Information consistent with multiple sclerosis 17
18 18 years of age or older Dementia Agents (High Risk Medications) Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication, OR, 2.) Patient has already tried and failed any ONE nonhigh risk formulary alternative (donepezil or galantamine) Required_Medical_Information Applies to patients 65 years or older Effient Patients with active pathological bleeding or history of TIA or stroke. Patients over 75 years of age who do not have high risk situations such as diabetes or a history of prior MI. Required_Medical_Information Documented treatment failure or intolerance to Plavix. Elaprase 18
19 Required_Medical_Information Diagnosis of Hunter syndrome (Mucopolysaccaridosis II or MPS II) Eleyso Required_Medical_Information Diagnosis of type 1 Gaucher disease 18 years of age or older Eligard, leuprolide Required_Medical_Information Must have a dx of at least one: Prostatic Carcinoma, Endometroisis, Uterine Leiomyomata (Fibroids), Central Precocious Puberty, Amenorrhea. Patient must be at least 18 years of age for all diagnoses, except for central precocious puberty 3 mo - 2 yrs (diagnosis dependent) Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Applies to new starts only for Prostatic Carcinoma. Emsam 19
20 Required_Medical_Information Failure of two (2) preferred antidepressants which should be from different classes of antidepressants, one of which should be Mirtazapine orally disintegrating tablets for patients unable to swallow tablets/capsules Patient must have tried at least 2 of the following Preferred agents, one which should be mirtazapine ODT: Fluoxetine capsules, Paroxetine, Citalopram, Bupropion, Mirtazapine/ Mirtazapine ODT, Trazodone, Amitriptyline, or Venlafaxine. Recommended treatment dose of Emsam is 6mg/24hr, maximum dose is 12mg/24hr. ONLY APPLIES TO NEW STARTS. Enbrel Patients with sepsis or active infection Rheumatoid Arthritis(RA): diagnosis of moderate to severe, active RA and documented failure of adequate trial, defined by the ACR, of one DMARD (Methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, azathioprine) and one NSAID (ibuprofen, naproxen, ketoprofen, meloxicam). Ankylosing Spondylitis: documented failure of maximum doses of at least 2 nonsteroidal anti-inflammatory drugs (NSAIDS) OR a cyclo-oxygenase (COX)-2-selective inhibitor. Psoriatic arthritis: diagnosis of moderate to severe disease with documented intolerance to at least 2 different preferred drugs. Preferred drugs include: DMARD s methotrexate, sulfasalazine, hydroychloroquine, azathioprine, lefludomide AND/OR NSAIDs ibuprofen, naproxen, ketoprofen, meloxicam. Plaque Psoriasis: Failure of two oral agents including methotrexate and a steroid OR Puva therapy. One of the treatments listed below: The use of topical steroids. The use of either Tazorac (tazorotene), Methotrexate Cyclosporine, UVB Required_Medical_Information phototherapy and/or PUVA therapy. 20
21 Epogen Pre-treatment Hct greater than 36%, patients not receiving iron supplementation if iron stores are inadequate, unspecified diagnosis of anemia, uncontrolled hypertension. Patients with an allergy to albumin, or any component of epoetin or allergy to mammalian cell-derived products Diagnosis with corresponding criteria outlined below, no active gastrointestinal bleed and lab data within 30 days prior to request. Anemia associated with one of the following: Chronic renal failure patients on dialysis with hgb less than 11g/dL (prior to treatment) or non dialiysis patients with hgb less than 10g/dL AND transferrin saturation should be at least 20% AND ferritin at least 100ng/mL. Zidovudine-treated HIV-infected patients with zidovudine dose less than 4,200 mg/week. Hgb below 10g/dL for initiation, serum erythropoietin levels 500mUnits/mL or less, Serum ferritin greater than100ng/ml, and transferrin sat.greater than 20%. Continuation of therapy is approved for hgb level less than 12g/dL. Anemia due to chemotherapy treatment of non-myeloid malignancies (where anemia is not caused by other factors) and hgb prior to therapy initation is less than 10g/dL (or Hct is less than 30%), continuation of therapy during concomitant chemotherapy requires Hgb less than 12 g/dl. Reduction of allogenic blood transfusion for patients scheduled to undergo elective, non-cardiac, nonvascular surgery with anemia and hemoglobin greater Required_Medical_Information than10 g/dl but less than 12 g/dl. For patients with cancer: prescribers must be under the ESA APPRISE Oncology program 3 months Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. 21
22 Fabrazyme Required_Medical_Information Diagnosis Fentora Coverage not provided in the management of acute or postoperative pain, opiod non-tolerant patients, patients with known intolerance or hypersensitivity to the drug or fentanyl Diagnosis of cancer and use is for breakthrough cancer pain AND other formulary short acting narcotics have been ineffective, not tolerated, or contraindicated AND patient is opioid tolerant and taking at least 60 mg morphine/day or an equianalgesic dose of another opioid for a week or Required_Medical_Information longer Patient must be at least 18 years of age 6 months Patient must have tried and failed or not responded to the following formulary short acting narcotics, Oxycodone and morphine. Ferriprox 22
23 Required_Medical_Information Diagnosis of transfusional iron overload due to thalassemia syndromes AND patient has failed prior chelation therapy with Desferal or Exjade (failure is defined as a serum ferritin level greater than 2,500 mcg/l) or patient has a contraindication or intolerance to Desferal or Exjade AND Patient has an absolute neutrophil count greater than 1.5 x 109/L. For renewal, patient has experienced at least a 20% reduction in serum ferritin levels and has an absolute neutrophil count greater than 0.5 x 109/L Firazyr Diagnosis of hereditary angioedema AND medication will Required_Medical_Information be used for the treatment of acute attacks. 18 years of age or older Flector Known hypersensitivity to diclofenac. Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Application to non-intact or damaged skin resulting from any etiology (e.g., exudative dermatitis, eczema, infected lesion, burns or wounds). Patient is receiving treatment for acute pain due to minor strains, sprains and contusions AND patient had experienced treatment failure with at least 2 prescription strength oral NSAIDs or patient has a documented Required_Medical_Information swallowing disorder. 23
24 14 days Forteo BMD scan with a T score of -2.5 or less AND High risk of fracture or those with a history of a previous fracture who have failed treatment with bisphosphonates. Member has had at least one fracture or has multiple risk factors for fracture OR member has BMD screening results of -2.5 or below AND member has had a 3 month trial, failure or adverse reaction to 1 oral bisphosphonate (alendronate Required_Medical_Information and ibandronic acid) and Boniva Inj. Preferred bisphosphonate agents include: Alendronate,Ibandronic Acid, and Boniva. Gastrointestinal Agents (High Risk Medications) Required_Medical_Information Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication Applies to patients 65 years or older 24
25 Gattex Active gastrointestinal malignancy (gastrointestinal tract, hepatobiliary, pancreatic), colorectal cancer, or small bowel cancer Diagnosis of short bowel syndrome AND patient is receiving specialized nutritional support (i.e. parenteral Required_Medical_Information nutrition) 18 years of age or older For renewal, patient has a reduced need for parenteral support (20% reduction) after at least 6 months of therapy. Gilenya Required_Medical_Information Patient is diagnosed with a relapsing form of MS. AND, Has had a trial and failure or intolerance to one of the following preferred therapies: Avonex or Betaseron Patient is 18 years of age or older Patient should be monitored following the first dose for signs and symptoms of bradycardia. Glassia IgA deficiency with known anti-iga antibody, current smoker 25
26 Required_Medical_Information Diagnosis of emphysema AND patient has alpha-1 proteinase inhibitor deficiency AND patient has a high-risk phenotype (PiZZ, PiZ(null), Pi(null) (null), or other phenotype associated with serum alpha-1 antitrypsin concentrations of less than 11 um/l (80 mg/dl). Gleevec Required_Medical_Information Diagnosis Prescribing physician must be a hematology/oncology specialist or have consulted with one ONLY APPLIES to NEW STARTS Humira Patients with mild rheumatoid arthritis, patients with mild Crohn s disease, patients with an active, serious infection, patients with a latent tuberculosis infection, concurrent use of anakinra 26
27 Required_Medical_Information Rheumatoid and Psoriatic arthritis: Patient has had an inadequate response to one or more disease modifying antirheumatic drugs (DMARDS): Methotrexate, Sulfasalazine, hydroxychloroquine, injectable gold, azathioprine, or penicillamine.(humira can be used in combination with methotrexate for patients who do not respond adequately to methotrexate alone.) Juvenile rheumatoid arthritis: diagnosis of moderate to severe, active polyarticular JIA and documented failure of methotrexate, following an appropriate treatment period, and one (preferably ibuprofen, naproxen or meloxicam). Moderate to Severe Active Crohn's disease: Patient has had inadequate response to one or more of the following: Sulfasalazine or azathioprine only, oral 5-ASA products (mesalamine, Asacol, Pentasa, Apriso, etc.), corticosteroids (Entocort EC, prednisone, etc.). Ankylosing Spondylitis: Non-therapeutic response to the maximum tolerated dose of at least two nonsteroidal antiinflammatory drugs (NSAIDS: sulindac, naproxen, diclofenac) or including a cyclo-oxygenase (COX)-2- selective inhibitor Celebrex. Plaque Psoriasis - At least 2 of the following treatment:: The use of topical steroids, the use of either Tazorac (tazorotene), Methotrexate, Oxsoralen, UVB phototherapy and/or PUVA treatment. Ilaris Diagnosis of cryopyrin-associated period syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS), or Systemic Juvenile Idiopathic Arthritis (SJIA). Required_Medical_Information 2 years of age or older for SJIA 27
28 Prescribed by or in consultation with or recommendation of, an immunologist, allergist, dermatologist, rheumatologist, neurologist, or other medical specialist Approve doses based on FDA labeling Incivek Pregnant. Unwilling to comply with required contraception methods. Co-administration with alfuzosin, cisapride, dihydroergotamine, drosperinone, ergonovine, ergotamine, lovastatin, methylergonovine, midazolam (oral), pimozide, rifampin, sildenafil (Revatio), simvastatin, St. John's wort, tadalafil (Adcirca), triazolam Diagnosis of chronic hepatitis C genotype 1 with compensated liver disease AND medication will be used with ribavirin and peginterferon alfa AND Has not previously failed a treatment regimen with a hepatitis C Required_Medical_Information protease inhibitor. Patient is 18 years of age or older Initial - 8 weeks. Renewal - 4 weeks for a total of 12 weeks. For renewal, patient continue to receive concurrent therapy with ribavirin and peginterferon alfa AND viral load at week 4 is 1,000 IU/mL or less, the patient has not experienced a serious skin reaction while on therapy. Increlex Insulin-like growth factor therapy is considered NOT medically necessary when any of the following criteria are met: Final adult height has been reached as determined by the 5th percentile of adult height OR the bone epiphyses are closed OR the patient is older than 18 years of age. Required_Medical_Information Diagnosis, Labs (IGF-1, GH) 28
29 The patient is between 2 years -18 years old for Increlex therapy Licensed Practioner Infergen Uncontrolled depression. Autoimmune hepatitis or other autoimmune condition known to be exacerbated by interferon and ribavirin. Excluded from use with protease inhibitors as triple therapy. Required_Medical_Information For Hepatitis C: positive hepatitis C viral load. Prescribing physician must be gastroenterologist, hepatologist or infectious disease specialist Intron-A Uncontrolled depression. Solid organ transplant other than liver. Autoimmune hepatitis or other autoimmune condition known to be exacerbated by interferon and ribavirin. Excluded from use as triple therapy with protease inhibitors. 29
30 Required_Medical_Information Diagnosis of hairy cell leukemia OR Diagnosis of Condylomata acuminata OR Diagnosis of AIDS-related Kaposi's sarcoma OR Clinically aggressive follicular lymphoma and the medication will be used concurrently with anthracycline-containing chemotherapy or is not a candidate for anthracycline-containing chemotherapy OR Malignant melanoma and the request for coverage is within 56 days of surgery and the patient is at high risk of disease recurrence OR Diagnosis of chronic hepatitis B with compensated liver disease and patient has evidence of hepatitis B viral replication and patient has been serum hepatitis B surface antigen-positive for at least 6 months OR DIagnosis of chronic hepatitis C with compensated liver disease and is receiving combination therapy with ribavirin, unless ribavirin is contraindicated. 1 yr chronic Hep C, 6 mo-1yr Hep B, All other approved indications - plan year ONLY APPLIES to NEW STARTS for Cancer Patients. Itraconazole Coadministration with cisapride, dofetilide, oral midazolam, pimozide, levacetylmethadol, quinidine, lovastatin, simvastatin, triazolam, ergot alkaloids metabolized by CYP3A4 (such as dihydroergotamine, ergometrine, ergotamine and methylergometrine), congestive heart failure or history of (capsules for treatment of onychomycosis), pregnant women or women contemplating pregnancy (capsules for treatment of onychomycosis), hypersensitivity to itraconazole. Onychomycosis: documented positive KOH test or other lab documenting diagnosis AND trial/failure or contraindication to terbinafine and topical ciclopirox. For Required_Medical_Information Aspergillosis, histoplasmosis, or blastomycosis: Approve. 30
31 Juxtapid Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests. Pregnancy. Concomitant use with strong or moderate CYP3A4 inhibitors. Diagnosis of homozygous familial hypercholesterolemia AND Medication will be used as adjunct to a low-fat diet and other lipid-lowering treatments AND Patient has tried and had an inadequate response or intolerance to statins AND Patient has tried and had an inadequate response or Required_Medical_Information intolerance to the following: lipid apheresis. Initial - 6 months. Renewal - For renewal, patient has responded to therapy with a decrease in LDL levels. Kalydeco Diagnosis of cystic fibrosis AND Patient has a known G551D mutation on at least one allele in the cystic fibrosis transmembrane conductance regulator gene documented by an FDA-cleared cystic fibrosis-mutation test that Required_Medical_Information includes measurement of the G551D mutation. 6 years of age or older Kineret 31
32 Diagnosis of moderate to severe rheumatoid arthritis and patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs)for at least 3 consecutive months OR Diagnosis of cryopyrin-associated periodic syndrome (CAPS) with neonatal-onset multisystem Required_Medical_Information inflammatory disease (NOMID). 18 years of age or older for rheumatoid arthritis For CAPS, diagnosed by, or upon consultation with or recommendation of, an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist. 6 mo-refractory chronic infantile neurological, cutaneous and articular syndrome, 1 yr-all others Patient has been tested for TB and latent TB has been ruled out or is being treated. Dosing as per the FDA labeling for rheumatoid arthritis. Kuvan Diagnosis of phenylketonuria (PKU) and patient is and will Required_Medical_Information be maintained on a phenylalanine-restricted diet 2 months to determine response, if response is positive, then approve for remainder of plan year. Response is defined as a 20% or greater reduction of blood Phe level from baseline during treatment for 1 2 months Kynamro 32
33 Required_Medical_Information Moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests. Diagnosis of homozygous familial hypercholesterolemia AND Medication will be used as adjunct to a low-fat diet and other lipid-lowering treatments AND Patient has tried and had an inadequate response or intolerance to statins AND Patient has tried and had an inadequate response or intolerance to at least one of the following: ezetimibe, cholestyramine, or lipid apheresis. Initial - 6 months. Renewal - For renewal, patient has responded to therapy with a decrease in LDL levels. Letairis Letairis: known or suspected pregnancy Diagnosis of PAH with WHO class II or III symptoms, a negative response to the acute vasoreactivity test, and documented trial/failure to sildenafil or Adcirca. The dose/quantity requested must be supported by one of the three CMS accepted compendia (DrugDex, USP or AHFS) or a published, peer reviewed article found on Medline with the supporting documentation in such literature being Required_Medical_Information specific to that indication. Must be a provider enrolled in the Letairis Education Access Program (LEAP) Leukine 33
34 Required_Medical_Information Diagnosis of one of the following: A) Patient has undergone allogeneic or autologous bone marrow transplant (BMT) and engraftment is delayed or failed and Patient does not have excessive leukemic myeloid blasts in bone marrow/peripheral blood (more than 10%) OR B) Patient is undergoing autologous peripheral-blood progenitor cell transplant to mobilize progenitor cells for collection by leukapheresis OR C) Medication will be used for myeloid reconstitution after an autologous or allogeneic BMT OR D) Patient has acute myeloid leukemia and administration will be after completion of induction chemotherapy. Linzess Mechanical gastrointestinal obstruction. Diagnosis of irritable bowel syndrome-constipation for at least 12 non-consecutive weeks and patient has tried and failed increasing fluid and fiber intake and patient has tried and failed or has an intolerance to osmotic laxatives, stimulant laxatives or probiotics OR Diagnosis of chronic idiopathic constipation for at least 3 months and patient has tried and failed increasing fluid and fiber intake and patient has tried and failed or has an intolerance to osmotic Required_Medical_Information laxatives, stimulant laxatives and stool softeners. 18 years of age or older Initial - 4 months. Renewal - Lumizyme, Myozyme 34
35 Required_Medical_Information Diagnosis: 1) Lumizyme used for late (non-infantile) onset Pompe disease (GAA) deficiency and the patient does not have evidence of cardiac hypertrophy. 2) Myozyme used for patients with infantile-onset Pompe disease (GAA deficiency). Lyrica Approve for the diagnosis of seizure disorder. For post herpetic neuralgia, trial and failure of preferred alternative, gabapentin is required. For Fibromyalgia: trial and failure or intolerance to Cymbalta is required. For Diabetic Peripheral Neuroathy trial and failure or intolerance to Cymbalta is Required_Medical_Information required. ONLY APPLIES TO NEW STARTS for Seizure Disorders. Mozobil Pregnant. Breast feeding. Patient is to undergo autologous stem cell transplantation for the treatment of non-hodgkin's lymphoma or multiple myeloma AND Patient will concomitantly receive a daily dose of a granulocyte colony-stimulating factor (G-CSF) for 4 days prior to the first evening dose of Mozobil and on Required_Medical_Information each day prior to apheresis while using Mozobil. 4 days 35
36 Neulasta Required_Medical_Information Diagnosis, chemo regimen, patient history when applicable. Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Forward to clinical pharmacist to review. Neumega Documented diagnosis of Chemo-induced thrombocytopenia AND Platelet count less than 50,000 Required_Medical_Information cells/microliter. Certified hematologist and/or oncologist Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Neupogen 36
37 Required_Medical_Information Diagnosis of the any of the indications and the following information must be obtained before approval is authorized: patient s weight, most recent (within the past week) CBC with differential or absolute neutrophil count (ANC) (for chemotherapeutic regimens where patient has had history of significant neutropenia while on chemotherapy, provide CBC with diff. or ANC of last chemo cycle where patient experienced neutropenia), dose to administer, duration of therapy, target ANC or target WBC. Clinical trial data shows no clinical benefit seen once an ANC is greater than 10,000/mm3. Home or LTC administration covered under Medicare Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Octreotide, Sandostatin, Zorbtive Diagnosis of acromegaly OR Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea and flushing episodes OR Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse Required_Medical_Information watery diarrhea. Labs, IGF-1, Glucose. Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Oral Estrogens (High Risk Medications) 37
38 Required_Medical_Information Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication Applies to patients 65 years or older Orencia Moderate to severe rheumatoid arthritis. The patient must have had an inadequate response to conventional treatment including methotrexate with or without one or more disease modifying anti- rheumatic drugs (DMARDs) +/- NSAIDs unless contraindicated or intolerant.the patient has had an inadequate response to one TNF antagonist therapy Remicade, Humira, or Enbrel. Moderate to severe polyarticular juvenile idiopathic arthritis and patient had an inadequate response, intolerance or contraindication to one or more non-biologic DMARDs for at least 3 consecutive months and patient had an inadequate response to one or more tumor necrosis factor inhibitors. An inadequate response can be defined as therapy was ineffective, not tolerated, or other clinical circumstance exists that Required_Medical_Information precludes use. Licensed Practioner highly familiar with the use and monitoring of special biologic response modifiers Pegasys 38
39 Required_Medical_Information Hepatitis C: positive hepatitis C viral load, with compensated liver disease AND no signs or symptoms of jaundice, ascites, active gastrointestinal bleeding, and encephalopathy. Required information for HCV:Baseline serunm HCV RNA and Statement indicating Hep C genotype. For Hepatitis B with compensated liver disease and evidence of viral replication and live inflammation. Peg-Intron Approved for the following diagnosis.hepatitis C AND the following labs are provided: HCV RNA levels, AST/ALT Required_Medical_Information levels, genotype, with or without results of liver biopsy. Prolastin-C IgA deficiency with known anti-iga antibody Required_Medical_Information Diagnosis of emphysema AND patient has alpha-1 proteinase inhibitor deficiency AND patient has a high-risk phenotype (PiZZ, PiZ(null), Pi(null) (null), or other phenotype associated with serum alpha-1 antitrypsin concentrations of less than 11 um/l (80 mg/dl) 39
40 Promacta Diagnosis of one of the following: A) Relapsed/refractory chronic immune (idiopathic) thrombocytopenic purpura (ITP) for greater than 6 months AND Baseline platelet count is less than 50,000/mcL AND Degree of thrombocytopenia and clinical condition increase the risk of bleeding AND Patient had an insufficient response, intolerance, contraindication to corticosteroids or immune globulin or inadequate response or contraindication to splenectomy, B)Chronic hepatitis C and patient has thrombocytopenia defined as platelets less than 90,000/mcL for initiation (pre-treatment) of interferon Required_Medical_Information therapy. Qualaquin Coverage is not provided for patients with any of the following contraindications to therapy: prolongation of QT interval, glucose-6-phosphate dehydrogenase (G6PD) deficiency, myasthenia gravis, Known hypersensitivity to quinine, mefloquine, or quinidine, or optic neuritis. Patient is being treated for uncomplicated Plasmodium Required_Medical_Information falciparum malaria Patient is 16 years of age or older 1 month 40
41 Relistor Coverage is not provided for use nausea, vomiting, pruritis, or urinary retention related to morphine or other opioids. Diagnosis of opioid-induced constipation AND Patient has used opioid medication for a minimum of 2 weeks AND Patient is experiencing fewer than 3 bowel movements in a week or no bowel movement for longer than 2 days AND Patient is diagnosed with an advanced illness (e.g., incurable cancer, end-stage chronic obstructive pulmonary disease/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS, etc.) AND Patient is receiving palliative care AND Patient has tried and had an insufficient response to at least 2 formulary agents: lactulose, PEG 3350 or Amitiza. Required_Medical_Information 4 Months Remicade Diagnosis, AND documentation of trial and failure or intolerance with the following: Rheumatoid Arthritis: Either Methotrexate OR generic leflunomide (Arava). Ankylosing Spondylitis: One nonsteroidal anti-inflammatory drugs (NSAIDS) OR a cyclo-oxygenase (COX)-2-selective inhibitor. Chronic Plaque Psoriasis: Member must have tried a DMARD in the past year. Psoriatic Arthritis: The member must have used two corticosteroids. Moderately to severely active ulcerative colitis. The member must have an inadequate response to conventional therapy including: Required_Medical_Information 5-aminosalicylic acids (5-ASAs) OR Corticosteroids. 41
42 Moderately active Crohn's disease: Inadequate response to Entocort EC. Revlimid Diagnosis of multiple myeloma: LABS, Platelet count, ANC, pregnancy test if female. Diagnosis of transfusiondependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Diagnosis of mantle cell lymphoma (MCL): documentated treatment with at least 1 prior agent, either Velcare or Rituxan, AND Labs including ANC and platelet count, pregnancy test if female. Required_Medical_Information 6 months Patient is enrolled in the RevAssist Program. ONLY APPLIES to NEW STARTS Sabril 42
43 Required_Medical_Information Diagnosis and treatment failure or intolerence with one or more of lower tier AED drugs: carbamazepine, phenytoin, lamotrigine, valproic acid, levetiracetam. Neurologist ONLY APPLIES TO NEW STARTS Somatropin Growth promotion in pediatric patients with closed epiphyses, evidence of active malignancy, progression of any underlying intracranial lesion or actively growing intracranial tumor, acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure, active proliferative or severe nonproliferative diabetic retinopathy, or in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. 43
44 Required_Medical_Information NEW THERAPY: Children: Criteria 1, 2 or 3 are required PLUS one below for approval x 1 year. 1. Child has hypopituitarism. 2. Child has failed two provocative growth hormone tests. 3. Child is to be treated for short stature associated with Turner Syndrome. PLUS ONE OF THESE A) A height of greater than 2.5 standard deviations below the median for age. B) A yearly growth rate of less than 4.5 cm/yr. C) A bone age of 2 standard deviations below chronological age. D) For Turner's Syndrome only - must supply height information- 1. Present height below 5th percentile 2. A height of greater than 2.0 standard deviations below the median for age. If none of the information above is provided send to Clinical Pharmacist. Adults (new therapy) MD must provide one of the following diagnosis: 1. Adult growth hormone deficiency 2. Cachexia or 3. HIV / AIDS wasting, or 4. Short bowel syndrome. If diagnosis is growth hormone deficiency, MD must document failure of two growth hormone tests. If diagnosis is cachexia or HIV / AIDS wasting, must answer YES to patient receiving concomitant antiretroviral therapy. If answer is yes approve for Serostim only. If diagnosis is short bowel syndrome, must answer YES to patient receiving specialized nutritional support. If answer is yes approve for Zorbitive 8mg/day x 4 weeks only. 4 weeks (adults with short bowel syndrome), (all other diagnoses) Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Somavert Hypersensitivity to pegvisomant, polyethylene glycol, or any component of the formulation Diagnosis of acromegaly AND Inadequate response to surgery and/or radiation therapy and/or other medical therapies (such as dopamine agonists and/or somatostatin analogues) or patient is not a candidate for any of those Required_Medical_Information treatment options. 44
45 Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. Sulfonylureas (High Risk Medications) Diagnosis: AND, 1.) The prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 and older) and wishes to proceed with the originally prescribed medication, OR, 2.) Patient has tried and failed ONE non-high risk formulary alternative (glipizide) Required_Medical_Information Applies to patients 65 years or older Tarceva Diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer and Tarceva will be used in combination with gemcitabine OR Diagnosis of locally advanced or metastatic (stage III or IV) non-small cell lung cancer with one of the following: A) failure with at least one prior chemotherapy regimen and Tarceva will be used as monotherapy, or B) no evidence of disease progression after four cycles of first-line platinum-based chemotherapy and Tarceva will be used as maintenance treatment and Tarceva will be used as monotherapy, or C) Patient has Required_Medical_Information known active epidermal growth factor receptor (EGFR) 45
46 mutation or gene amplification and Tarceva will be used first-line. Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. ONLY APPLIES to NEW STARTS Testosterone Male patients with normal or above normal testosterone levels (normal equal to ng/dl or mmol), breast cancer in males, hypersensitivity to testosterone or any component of the product, pregnancy, known or suspected prostate cancer, use of the gel or patch in women Diagnosis of hypogonadism (primary or hypogonadotropic) AND patient is male AND patient's serum testosterone (total or free) value and the laboratory reference value range reported by laboratory service AND diagnosis has been confirmed by a low-for-age serum testosterone (total or free) level defined by the normal laboratory reference Required_Medical_Information value Home or LTC administration covered under Medicare Part D. Physician office or healthcare setting administration, redirect for Medicare Part B coverage. 46
47 Tetrahydrocannabinol Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy, AND Failure to 5HT-3 receptor antagonist, AND Failure to one of the following agents: Antihistamine, Corticosteroid, Prokinetic agent, Antipsychotic. AIDS Anorexia: Diagnosis of anorexia with weight loss in patients Required_Medical_Information with AIDS. CINV: 6 months, AIDS anorexia: Through benefit year CINV: tetrahydrocannabinol will be approved for continuation covered under Part B when patient is receiving chemotherapy Tracleer Receiving concomitant cyclosporine A or glyburide therapy. Aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin at least 2 times the upper limit of normal. Diagnosis of pulmonary arterial hypertension that was confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.) AND Patient has WHO Group I PAH AND Patient has New York Heart Association (NYHA) Functional Class II-IV AND pregnancy must be excluded prior to the start of therapy and will be prevented thereafter with reliable contraception Required_Medical_Information in female patients of reproductive potential. Prescription is written by or in consultation with a pulmonologist or cardiologist 47
Biologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationCo-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationThe following should be current within the past 6 months:
EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationMEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
More informationPrior Authorization Form
Prior Authorization Form Growth Hormone This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationMEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationRheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationPATIENT / VISIT INFORMATION PATIENT INFORMATION
PATIENT / VISIT INFORMATION PATIENT INFORMATION Name of Patient: Date of Birth: Date of Visit: VISIT INFORMATION Please complete this form in its entirety, and present it to the registration desk when
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationClinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW
Clinical Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW NQF 0105 PQRS 9 NQF 0002 PQRS 66 Antidepressant Medication Management Appropriate Testing for Children with Pharyngitis (2-18 years)
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationSOUTH TAMPA MULTIPLE SCLEROSIS CENTER
SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/CARE GIVER QUESTIONNAIRE DEMOGRAPHIC INFORMATION Patient's Name: City: State: Zip Code: Phone: Marital Status: Spouse/Care Giver Name: Phone (H) (W) Occupation:
More informationSECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationHepatitis C Treatment Expansion Initiative Multi-Site Conference Call. March 16, 2011
Hepatitis C Treatment Expansion Initiative Multi-Site Conference Call March 16, 2011 Case Presentations Kansas City Free Health Clinic Carilion Clinic Didactic Session Challenges in Determining HCV Treatment
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationRheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
More informationMANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationORAL MEDICATIONS FOR MS! Gilenya and Aubagio
ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012
More informationPatient Information Form Pain Management Center at Phoebe
Patient Information Form Pain Management Center at Phoebe Please complete the following form, so that we may facilitate your visit Occupation: or (circle) Retired, Disabled Homemaker, Full time student
More informationICD-9-CM/ICD-10-CM Codes for MNT
/ Codes for MNT ICD (International Classification of Diseases) codes are used by physicians and medical coders to assign medical diagnoses to individual patients. It is not within the scope of practice
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationPreoperative Laboratory and Diagnostic Studies
Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no
More informationMedical Specialties Guide
Medical Specialties Guide Allergy And Immunology Specialists in this field treat disorders related to how the body reacts to foreign substances. They treat such things as seasonal allergies, eczema, asthma,
More informationACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria
Cigna Medicare Rx (PDP) Medicare Part D Prescription Drug Plans 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary Prior Authorization ACTEMRA Products Affected Actemra PA Details Age Other Authorization
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationPsoriasis and Psoriatic Arthritis Alliance
Psoriasis and Psoriatic Arthritis Alliance A principal source of information on psoriasis and psoriatic arthritis ) Treatments for Psoriatic Arthritis overview Although psoriatic arthritis is a chronic
More informationDallas Neurosurgical and Spine Associates, P.A Patient Health History
Dallas Neurosurgical and Spine Associates, P.A Patient Health History DOB: Date: Reason for your visit (Chief complaint): Past Medical History Please check corresponding box if you have ever had any of
More informationPreconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More informationMedicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
More informationLimited Pay Policy (L-222B) - Underwriting Guidelines
Limited Pay Policy (L-222B) - Underwriting Guidelines 1 Addiction/Abuser Drug - Past or Present Presently Recovered - AA for last 2 years 2 Aids 3 Alcoholic Presently Recovered - AA for last 2 years 4
More informationAsk Your Doctor if There May Be a SMARTER CHOICE
If you have osteoarthritis, rheumatoid arthritis or ankylosing spondylitis, Could Your NSAID Pain Medicine Be Hurting Your Stomach? Ask Your Doctor if There May Be a SMARTER CHOICE 1 of 8 Making Smart
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationNew England Pain Management Consultants At New England Baptist Hospital
New England Pain Management Consultants At New England Baptist Hospital Pain Management Center Health Assessment Dear New Pain Management Patient, Welcome to the New England Pain Management Consultants
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationAutoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationSOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE
SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE DEMOGRAPHIC INFORMATION Patient Name: Date: Address: City: State: Zip Code Best Phone Number: Marital Status Phone (H): (W) (Cell):
More informationHepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationMale New Patient Package
Male New Patient Package The contents of this package are your first step to restore your vitality. Please take time to read this carefully and answer all the questions as completely as possible. Thank
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationStepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
More informationPage 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015
More informationBiogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812
NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationto Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.
2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan
More informationGreat-West s Drug Prior Authorization
Great-West s Drug Prior Authorization Great-West Life s prior authorization process is designed to provide an effective approach to managing claims for specific prescription drugs. Approval for coverage
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationMEDICAL HISTORY AND SCREENING FORM
MEDICAL HISTORY AND SCREENING FORM The purpose of preventive exams is to screen for potential health problems and provide education to promote optimal health. It is best practice for chronic health problems
More informationLiver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:
Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP Primary Care Provider: If you are considering hepatitis C treatment, please read this treatment
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 1, 2014 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationHepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This
More informationLEMTRADA REMS Education Program for Prescribers
For Prescribers LEMTRADA REMS Education Program for Prescribers This education program includes information about: The LEMTRADA REMS Program requirements Serious risks of autoimmune conditions, infusion
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationCLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments
Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationINSTRUCTIONS CHECKLIST
These instructions have been designed for you to simplify the application process. Read these instructions in full before you begin. If you have any questions, please call Medipac for further assistance
More informationDrug Formulary Update, July 2013
Drug Formulary Update, July 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
More informationProgressive Care Insurance for life A NEW TYPE OF INSURANCE
Progressive Care Insurance for life A NEW TYPE OF INSURANCE New Progressive Care from Sovereign Progressive Care is a type of insurance that is new to New Zealand. It s not a traditional all-or-nothing
More informationThymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
More information